Azitra Inc (AZTR)

Azitra's stock price has declined significantly over the past year. In May 2026, Azitra announced a new U.S. patent for ATR-12, but the stock price declined. In April 2026, Azitra presented on ATR-01, pursued reverse stock splits, and awarded stock options to executives, with momentum indicators turning positive. In March 2026, Azitra announced a private placement financing, causing the stock to jump, and received a NYSE non-compliance notice. In February 2026, Azitra reported full-year 2025 results and initiated the ATR-04 Phase 1/2 trial. In November 2025, Azitra reported Q3 2025 earnings and received a NYSE non-compliance notice. The stock has recently shown stronger performance in shorter time frames.

The provided information does not contain specific details regarding demand seasonality for Azitra, Inc.'s products and services. Demand for its products is likely driven by disease prevalence, treatment efficacy, physician adoption, and market access rather than seasonal consumer patterns.

Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, operating within the Biotechnology industry. The company develops therapies using the human microbiome, engineered proteins, and topical live biotherapeutic products to treat skin diseases. Azitra's platform includes a microbial library and AI/ML technology for screening drug-like molecules, with a product pipeline focused on genetically engineered strains of Staphylococcus epidermidis. Key programs include ATR-12 for Netherton syndrome, ATR-04 for EGFRi-associated rash, and ATR-01 for ichthyosis vulgaris. Azitra also has a joint development agreement with Bayer.

Azitra, Inc. is headquartered in Branford, Connecticut, United States, with its primary focus for therapy development and clinical trials within the U.S. While the company aims to expand internationally through partnerships, specific international operations are not detailed.

Azitra's brand reputation is shaped by its clinical progress, financial activities, and compliance with listing standards. Positive events include the advancement of clinical programs, positive preclinical data for ATR-01, a patent grant for ATR-12, successful financing rounds, and presentations at conferences. Negative events include NYSE American non-compliance notices, share dilution, stock price decline, and concerns about cash runway. Overall, Azitra's reputation is that of an innovative biopharmaceutical company facing financial and regulatory challenges.

Azitra, Inc. has a mix of institutional and individual owners. Institutional shareholders own approximately 1.39% of the stock, while insiders own 98.08%, and retail investors own 0.53%. Major institutional owners include Geode Capital Management, Llc and DRW Securities, LLC. Major individual and insider owners include Aaron Gl Fletcher, Leslie W. Kreis, and Bayer Healthcare LLC. Shareholders have experienced substantial dilution in the past year.